MyDiabetesMyWay (MDMW) is a web-based platform/ smartphone app for people with diabetes, tethered to the healthcare system. It offers multimedia education, structured e-learning (QISMET approved), NHS health-record access, integration with home-recorded data, remote communication and highly tailored advice/ reports. MDMW has run nationally, since 2008, across NHS Scotland, and is implemented in 20% of NHS England through MyWay Digital Health. MDMW has more than 60,000 registrants (full data access) and more than 500,000 unique users (education platform); utilising over 250 multimedia educational resources, including >100 non-english language resources, and 7 times fully (QISMET) accredited structured education e-learning courses for type 1, type 2, gestational diabetes and diabetes prevention.
MDMW integrates with NHS records through linkages with GP, other NHS IT systems, and home-recorded data through device integrations (blood glucose, activity data) and manual data input (including blood pressure/ weight). MDMW enables remote communication with health care providers (secure messaging) and drives highly tailored advice and reports (data-algorithms). MDMW improves health outcomes (HbA1C, weight and blood pressure) with significant cost savings (ROI~ 5:1).
MyWay Digital Health has developed a complimentary clinician and population analytics solution (MyDiabetes Clinical), a diabetes electronic health record, remote communication platform encompassing clinician-facing decision support (improving guideline adherence), national KPI tracking, local audit functionality and predictive analytics for diabetes complications, health deterioration, diagnosis at individual/ population level.
MDMW awards include European e-health adopters (2017), Diabetes UK self-management (2015), Quality in Diabetes Care (2013) awards, Emerging Digital Health Company of the Year (Scotland Is) (2019). Wake (CEO) is a 2019 National Women in Innovation Award winner and NHS Innovation Accelerator fellow. MWDH have led Innovate UK SBRI/ Digital Health Catalysts/ Test-bed Projects (>£2.5m funding).
MyWay Diabetes systems are increasingly relevant given the disproportionate impact of COVID-19 on people with diabetes who constitute 40% of deaths. Severity of COVID-19 outcomes is linked closely to obesity/ poor diabetes/risk factor control. There is an urgent need for solutions to reduce face-to-face contact/ improve outcomes through remote patient-clinician communication, online education/ self-management. MyDiabetes Clinical can further risk-stratify populations enabling triage of those in need, given limited resources and risk associated with clinical contact.